Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. Garris CS, et al. Among authors: browning e. Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11. Immunity. 2018. PMID: 30552023 Free PMC article.
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma.
Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino C, Bhatia S, Gargosky S, Andtbacka RHI, Fox BA, Rosenblum MD, Daud AI. Algazi AP, et al. Among authors: browning e. Clin Cancer Res. 2020 Jun 15;26(12):2827-2837. doi: 10.1158/1078-0432.CCR-19-2217. Epub 2020 May 6. Clin Cancer Res. 2020. PMID: 32376655 Free PMC article. Clinical Trial.
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. Garris CS, et al. Among authors: browning e. Immunity. 2022 Sep 13;55(9):1749. doi: 10.1016/j.immuni.2022.07.021. Immunity. 2022. PMID: 36103861 No abstract available.
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.
Lee JY, Nguyen B, Mukhopadhyay A, Han M, Zhang J, Gujar R, Salazar J, Hermiz R, Svenson L, Browning E, Lyerly HK, Canton DA, Fisher D, Daud A, Algazi A, Skitzki J, Twitty CG. Lee JY, et al. Among authors: browning e. Mol Ther Oncolytics. 2022 Apr 18;25:174-188. doi: 10.1016/j.omto.2022.04.005. eCollection 2022 Jun 16. Mol Ther Oncolytics. 2022. PMID: 35592387 Free PMC article.
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI. Algazi A, et al. Among authors: browning e. Ann Oncol. 2020 Apr;31(4):532-540. doi: 10.1016/j.annonc.2019.12.008. Epub 2020 Feb 1. Ann Oncol. 2020. PMID: 32147213 Free article. Clinical Trial.
Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.
Telli ML, Nagata H, Wapnir I, Acharya CR, Zablotsky K, Fox BA, Bifulco CB, Jensen SM, Ballesteros-Merino C, Le MH, Pierce RH, Browning E, Hermiz R, Svenson L, Bannavong D, Jaffe K, Sell J, Foerter KM, Canton DA, Twitty CG, Osada T, Lyerly HK, Crosby EJ. Telli ML, et al. Among authors: browning e. Clin Cancer Res. 2021 May 1;27(9):2481-2493. doi: 10.1158/1078-0432.CCR-20-3944. Epub 2021 Feb 16. Clin Cancer Res. 2021. PMID: 33593880 Free PMC article. Clinical Trial.
Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
Ilyinskii PO, Roy CJ, O'Neil CP, Browning EA, Pittet LA, Altreuter DH, Alexis F, Tonti E, Shi J, Basto PA, Iannacone M, Radovic-Moreno AF, Langer RS, Farokhzad OC, von Andrian UH, Johnston LP, Kishimoto TK. Ilyinskii PO, et al. Among authors: browning ea. Vaccine. 2014 May 19;32(24):2882-95. doi: 10.1016/j.vaccine.2014.02.027. Epub 2014 Mar 1. Vaccine. 2014. PMID: 24593999 Free PMC article.
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.
Maldonado RA, LaMothe RA, Ferrari JD, Zhang AH, Rossi RJ, Kolte PN, Griset AP, O'Neil C, Altreuter DH, Browning E, Johnston L, Farokhzad OC, Langer R, Scott DW, von Andrian UH, Kishimoto TK. Maldonado RA, et al. Among authors: browning e. Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E156-65. doi: 10.1073/pnas.1408686111. Epub 2014 Dec 29. Proc Natl Acad Sci U S A. 2015. PMID: 25548186 Free PMC article.
84 results